期刊文献+

美罗华联合CHOP方案化疗治疗非霍奇金淋巴瘤疗效分析 被引量:4

下载PDF
导出
摘要 目的:观察分析美罗华联合CHOP方案化疗治疗非霍奇金淋巴瘤的临床疗效。方法:选择2008~2010年收治的B细胞非霍奇金淋巴瘤患者22例,随机分为治疗组(11例)和对照组(11例),治疗组采用美罗华联合CHOP化疗治疗,对照组采用单纯CHOP方案化疗,4个疗程后比较2组的临床疗效及不良反应。结果:治疗组总有效率为81.82%;对照组总有效率为63.64%;2组临床疗效差异有统计学意义(P<0.05)。2组不良反应差异无统计学意义(P>0.05)。结论:美罗华联合CHOP方案化疗治疗非霍奇金淋巴瘤临床有效率更高,不良反应轻微,值得临床上推广应用。
作者 宁瑞玲
出处 《中国社区医师(医学专业)》 2011年第12期59-59,共1页
  • 相关文献

参考文献5

二级参考文献36

  • 1叶煌阳,张映红.美罗华联合化疗治疗恶性淋巴瘤14例报告[J].临床肿瘤学杂志,2005,10(5):529-531. 被引量:9
  • 2林桐榆,张红雨,黄岩,管忠震,沈悌,石远凯,朱军,克晓燕,王华庆,沈志祥,于世英,刘霆,施笑利.R-CHOP与CHOP方案治疗初治弥漫大B细胞型淋巴瘤在中国的多中心随机对照研究[J].癌症,2005,24(12):1421-1426. 被引量:47
  • 3鲁明骞,黄慧强,徐光川,许新华,文采红,王杰,彭绪申.DHAP方案治疗复发难治性非霍奇金淋巴瘤的临床疗效观察[J].中华肿瘤防治杂志,2006,13(8):624-625. 被引量:13
  • 4Pand D, Moskowitzx CH, Zelenetz AD, et al. Rituximab for aggressive non-Hodgkin's tymphomas relapsing after or refractory to autologous stem cell transplantation. Cancer, 2002, 8 (5) : 371-376.
  • 5Vose JM, Link DK, Grossbard ML, et al. Phase Ⅱ study of rituxmiab in combination with CHOP chemotherapy in patients with previously untreated aggressive non-Hodgkins' lymphoma. J ClinOnco, 2001, 19: 389-397.
  • 6Coiffier B, Hrebrecht R, Morel P, et al. GELA study comparing CHOP and R-CHOP in elderly patients with DLCL: 3-year median follow-up with an analysis according to co-morbidity factiors. Hematol J, 2003, 4: 111-117.
  • 7Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy along in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the Mabthera International Trial (MINT) Group. Lancet Oncol, 2006, 7: 379-391.
  • 8Ghielmini M, Schmitz SF, Cogliatti SB, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly×4 schedule. Blood, 2004, 103: 4416-4423.
  • 9Marinus HJ, VanOers MD, Anton Hagenbeek MD, et al. Chimeric anti-CD20 monoclonal antibody (rituximab; mabthera) in remission induction and maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: Final analysis of a phase Ⅲ randomized intergroup clinical trial. Blood, 2005, 106: 353.
  • 10Howard S, Hochster MD, Edie W, et al. Maintenance Rituximab after CVP results in superior clinical outcome in advanced follicular lymphoma (FL) : Results of the E1496 phase Ⅲ trial from the eastern cooperative oncology group and the cancer and leukemia groupB. Blood, 2005, 106: 349.

共引文献21

同被引文献35

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部